Attovia Therapeutics, Inc. (ATTO) Stock Statistics & Valuation Metrics

Attovia Therapeutics, Inc. has a market cap or net worth of $697.09M. The enterprise value is ―.

Market Cap

$697.09M

Enterprise Value

―

Attovia Therapeutics, Inc. has 45,651,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

45,651,260

Owned by Insiders

47.28%

Owned by Institutions

5.98%

Attovia Therapeutics, Inc.’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -42.83%.

Return on Equity (ROE)

-0.40

Return on Assets (ROA)

-0.37

Return on Invested Capital (ROIC)

-42.83%

Return on Capital Employed (ROCE)

-0.43

Revenue Per Employee

30.68K

Profits Per Employee

-1.38M

Employee Count

44

Asset Turnover

0.01

Inventory Turnover

0.00

The current PE Ratio of Attovia Therapeutics, Inc. is -7.09. Attovia Therapeutics, Inc.’s PEG ratio is 0.07.

PE Ratio

-7.09

PS Ratio

1619.10

PB Ratio

11.79

Price to FCF

-15.19

Price to Operating Cash Flow

-98.69

PEG Ratio

0.07

In the last 12 months, Attovia Therapeutics, Inc. had revenue of 1.35M and earned -60.63M in profits. Earnings per share was -1.42.

Revenue

1.35M

Gross Profit

546.00K

Operating Income

-67.16M

Pretax Income

-60.63M

Net Income

-60.63M

EBITDA

-66.36M

Earnings Per Share (EPS)

-1.42

In the last 12 months, operating cash flow was -60.60M and capital expenditures -378,000, giving a free cash flow of -60.98M billion.

Operating Cash Flow

-60.60M

Free Cash Flow

-60.98M

Free Cash Flow per Share

-0.16

Attovia Therapeutics, Inc. pays an annual dividend of $1.71, resulting in a dividend yield of ―

Dividend Per Share

$1.71

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-4.84%

Earnings Yield

-5.40%

Beta

-0.73

52-Week Price Change

-30.27%

50-Day Moving Average

18.25

200-Day Moving Average

18.84

Relative Strength Index (RSI)

45.49

Average Volume (3m)

351.34K

Attovia Therapeutics, Inc. upcoming earnings date is ―, After Close (Confirmed).

Last Earnings Date

Sep 02, 2026

Next Earnings Date

―

Ex-Dividend Date

Nov 09, 2017

Attovia Therapeutics, Inc. as a current ratio of 14.20, with Debt / Equity ratio of 3.49%

Current Ratio

14.20

Quick Ratio

14.20

Debt to Market Cap

0.00

Net Debt to EBITDA

0.53

Interest Coverage Ratio

0.00

In the past 12 months, Attovia Therapeutics, Inc. has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Attovia Therapeutics, Inc. EV to EBITDA ratio is -16.96, with an EV/FCF ratio of -19.84.

EV to Sales

1555.76

EV to EBITDA

-16.96

EV to Free Cash Flow

-19.84

EV to Operating Cash Flow

-20.04

Attovia Therapeutics, Inc. has $395.94M in cash and marketable securities with $3.84M in debt, giving a net cash position of $392.10M billion.

Cash & Marketable Securities

$395.94M

Total Debt

$3.84M

Net Cash

$392.10M

Net Cash Per Share

$8.59

Tangible Book Value Per Share

$1.35

Gross margin is -8.44%, with operating margin of -18533.78%, and net profit margin of -16900.67%.

Gross Margin

-8.44%

Operating Margin

-18533.78%

Pretax Margin

-16900.67%

Net Profit Margin

-16900.67%

EBITDA Margin

-18379.33%

EBIT Margin

-12972.89%

The average price target for Attovia Therapeutics, Inc. is $41.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$41.00

Price Target Upside

168.50% Upside

Analyst Consensus

Strong Buy

Analyst Count

4

Revenue Growth Forecast

―

EPS Growth Forecast

―

Smart Score

7

AI Score

52